Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil.
Meier-Kriesche
Herwig-Ulf
HU
Davies
Neal M
NM
Grinyó
Josep
J
Heading
Robert
R
Mamelok
Richard
R
Wijngaard
Peter
P
Oellerich
Michael
M
Maes
Bart
B
D002986:Clinical Trials as Topic; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000379:methods; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D012107:Research Design
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid